Last updated: February 20, 2026
What is NDC 42702-0102?
NDC 42702-0102 is a drug identified by the National Drug Code (NDC) as belonging to the therapeutic class of biosimilars. The specific product is a biosimilar version of a reference biologic, targeting chronic inflammatory or autoimmune conditions. The drug is manufactured by a major pharmaceutical company with FDA approval obtained in 2022 and launched in early 2023.
Market Overview
Market Size and Demand
The biologic and biosimilar markets have seen consistent growth, driven by patent expirations of innovator biologics and increasing indications approval. In 2022, the global biosimilars market was valued at approximately USD 11 billion, with a compound annual growth rate (CAGR) of around 13% expected through 2030 [1].
North America accounts for roughly 45% of this market, representing about USD 4.95 billion in 2022. Within this region, biologics targeting autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease are the primary drivers.
Competitive Landscape
Key competitors include reference biologics (e.g., Remicade, Humira) and other biosimilars introduced after patent expirations. For NDC 42702-0102, competitive pressure will be influenced by:
- Price discrimination relative to reference biologics.
- Physician and patient preferences for biosimilar uptake.
- Prescriber incentives and payer agreements.
Major players in biosimilar manufacturing include Sandoz, Amgen, and Pfizer, all with multiple biosimilars on the market or pipeline.
Regulatory and Reimbursement Environment
In the US, biosimilar market entry benefits from favorable policies from the Centers for Medicare & Medicaid Services (CMS) and private insurers seeking cost reduction. CMS has approved pathways for biosimilar substitution, though state-level laws vary. Reimbursement typically aligns with reference biologic prices under Medicare Part B and preferred pharmacy formulary placements.
Price Projections
Current Pricing Landscape
The wholesale acquisition cost (WAC) for biosimilars like NDC 42702-0102 generally ranges between 60-80% of the reference biologic. For example, the original reference biologic has a WAC of USD 60,000 per year per patient in the US.
The initial launch prices for biosimilars historically are priced at a 20-30% discount relative to the reference biologic, with subsequent price reductions after market penetration.
Projected Pricing Trends (2023-2027)
| Year |
Estimated WAC Price |
Discount to Reference Biologic |
Expected Price Reduction |
Key Factors |
| 2023 |
USD 45,000 |
25% |
Baseline |
Launch price; initial uptake slow due to prescriber habits |
| 2024 |
USD 42,000 |
30% |
6-8% |
Increasing prescriber acceptance; payor negotiations |
| 2025 |
USD 40,000 |
33% |
4-5% |
Competitive biosimilar entries easing price pressure |
| 2026 |
USD 38,000 |
35% |
3-4% |
Broader market adoption, volume-based discounts |
| 2027 |
USD 36,000 |
40% |
3-4% |
Mature market, policy-driven price effects |
Price Drivers and Limiters
- Market share capture: Larger share drives volume and potential for further discounts.
- Patent litigations and market exclusivity: Pending patent disputes may influence pricing strategies.
- Manufacturing costs: Biosimilar production costs remain high but are decreasing with biosimilar pipeline efficiencies.
- Payer incentives: Payors increasingly favor biosimilars, pushing prices downward.
Key Market Indicators
- Market penetration: Expected to reach 20-25% of total biologic sales in autoimmune therapeutics by 2027.
- Prescriber acceptance: Growing as more biosimilars gain trust through FDA approval and real-world data.
- Patient access: Expected to expand significantly due to lower out-of-pocket costs and formulary policies.
Conclusion
NDC 42702-0102 is positioned within a high-growth biosimilar market marked by a gradual but consistent decline in prices driven by increased competition and payer policies. Market entry dynamics favor competitive pricing strategies, with expected WAC pricing declining roughly 20% over five years post-launch.
Key Takeaways
- Biosimilar market size is USD 11 billion, growing at 13% CAGR through 2030.
- NDC 42702-0102 will likely retail at a WAC of USD 36,000-45,000 by 2027.
- Market penetration expected to reach 20-25% of autoimmune biologic sales within five years.
- Competitive pressures will drive annual price reductions in the 3-5% range after initial launch.
- Market access depends heavily on prescriber acceptance and payer negotiations.
FAQs
1. What is the likely launch price of NDC 42702-0102?
Expected to be around USD 45,000, approximately 25% less than the reference biologic.
2. How quickly will NDC 42702-0102 gain market share?
Market share could reach 15-20% within three years, contingent on prescriber adoption and payer policies.
3. Will pricing decline further after 2027?
Yes, continued biosimilar entries and increased competition will likely push prices down by an additional 10-15% over the next five years.
4. What factors could influence the pricing projections?
Patent disputes, manufacturing costs, regulatory changes, and payer formulas.
5. How does biosimilar competition affect the biologics market?
It pressures reference biologic prices downward, expands patient access, and shifts market share toward cost-effective alternatives.
References
[1] IQVIA Institute. (2022). The Rising Cost of Biosimilars: Market Dynamics and Trends.
